Source: CURATED

Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 10157
Gene Symbol: AASS
AASS
Alpha-Aminoadipic Semialdehyde Deficiency Disease
0.300 Biomarker CTD_human

Entrez Id: 10157
Gene Symbol: AASS
AASS
Chemical and Drug Induced Liver Injury
0.300 Biomarker CTD_human Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model. 25231249

2015

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C4279912
Disease: Chemically-Induced Liver Toxicity
Chemically-Induced Liver Toxicity
0.300 Biomarker CTD_human Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model. 25231249

2015

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C3658290
Disease: Drug-Induced Acute Liver Injury
Drug-Induced Acute Liver Injury
0.300 Biomarker CTD_human Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model. 25231249

2015

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease
0.300 Biomarker CTD_human Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model. 25231249

2015

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C1262760
Disease: Hepatitis, Drug-Induced
Hepatitis, Drug-Induced
0.300 Biomarker CTD_human Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model. 25231249

2015

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0019193
Disease: Hepatitis, Toxic
Hepatitis, Toxic
0.300 Biomarker CTD_human Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model. 25231249

2015

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0268555
Disease: Hyperlysinemia, Periodic
Hyperlysinemia, Periodic
0.300 Biomarker CTD_human

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0543533
Disease: Hyperlysinemia, type I
Hyperlysinemia, type I
0.400 Biomarker GENOMICS_ENGLAND Identification of the alpha-aminoadipic semialdehyde synthase gene, which is defective in familial hyperlysinemia. 10775527

2000

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0543533
Disease: Hyperlysinemia, type I
Hyperlysinemia, type I
0.400 Biomarker GENOMICS_ENGLAND Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes. 27604308

2016

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0268553
Disease: Hyperlysinemias
Hyperlysinemias
0.720 GermlineCausalMutation ORPHANET Clinical, biochemical, molecular and therapeutic aspects of 2 new cases of 2-aminoadipic semialdehyde synthase deficiency. 23890588

2013

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0268553
Disease: Hyperlysinemias
Hyperlysinemias
0.720 Biomarker CTD_human

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0268553
Disease: Hyperlysinemias
Hyperlysinemias
0.720 Biomarker CLINGEN On the basis of these and other results, we propose that AASS catalyzes the first two steps of the major lysine-degradation pathway in human cells and that inactivating mutations in the AASS gene are a cause of hyperlysinemia. 10775527

2000

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0268553
Disease: Hyperlysinemias
Hyperlysinemias
0.720 Biomarker CLINGEN Hyperlysinemia is caused by mutations in AASS. 23570448

2013

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0268553
Disease: Hyperlysinemias
Hyperlysinemias
0.720 Biomarker CLINGEN Clinical, biochemical, molecular and therapeutic aspects of 2 new cases of 2-aminoadipic semialdehyde synthase deficiency. 23890588

2013

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0268553
Disease: Hyperlysinemias
Hyperlysinemias
0.720 GermlineCausalMutation ORPHANET Hyperlysinemia is caused by mutations in AASS. 23570448

2013

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0268553
Disease: Hyperlysinemias
Hyperlysinemias
0.720 Biomarker GENOMICS_ENGLAND Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes. 27604308

2016

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0268553
Disease: Hyperlysinemias
Hyperlysinemias
0.720 GermlineCausalMutation ORPHANET On the basis of these and other results, we propose that AASS catalyzes the first two steps of the major lysine-degradation pathway in human cells and that inactivating mutations in the AASS gene are a cause of hyperlysinemia. 10775527

2000

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0268553
Disease: Hyperlysinemias
Hyperlysinemias
0.720 Biomarker CLINGEN High-throughput discovery of novel developmental phenotypes. 27626380

2016

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0268553
Disease: Hyperlysinemias
Hyperlysinemias
0.720 Biomarker GENOMICS_ENGLAND

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0268553
Disease: Hyperlysinemias
Hyperlysinemias
0.720 Biomarker CLINGEN Conversion of lysine to saccharopine by human tissues. 4385118

1968

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0268553
Disease: Hyperlysinemias
Hyperlysinemias
0.720 Biomarker CLINGEN Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes. 27604308

2016

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C0268553
Disease: Hyperlysinemias
Hyperlysinemias
0.720 Biomarker GENOMICS_ENGLAND On the basis of these and other results, we propose that AASS catalyzes the first two steps of the major lysine-degradation pathway in human cells and that inactivating mutations in the AASS gene are a cause of hyperlysinemia. 10775527

2000

Entrez Id: 10157
Gene Symbol: AASS
AASS
CUI: C3714756
Disease: Intellectual Disability
Intellectual Disability
0.400 Biomarker GENOMICS_ENGLAND Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes. 27604308

2016

Entrez Id: 10157
Gene Symbol: AASS
AASS
Lysine Alpha-Ketoglutarate Reductase Deficiency Disease
0.500 Biomarker CTD_human